Pre-pandemic cross-reactive humoral immunity to SARS-CoV-2 in Africa: systematic review and meta-analysis

Short title: Pre-pandemic humoral SARS-CoV-2 immunity in Africa

John P.A. Ioannidis, MD, DSc[1], Despina G. Contopoulos-Ioannidis, MD[2]

1 Departments of Medicine, of Epidemiology and Population Health, of Biomedical Data Sciences, and of Statistics, and Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford CA, USA

2 Division of Pediatric Infectious Diseases, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA

Correspondence: John P.A. Ioannidis, MD, DSc, 1265 Welch Rd, SPRC, Medical School Office Building X306, Stanford, CA 94305, USA E-mail: jioannid@stanford.edu .

3446 words; 3 tables; 2 figures; supplement: supplementary references, 5 supplementary tables; abstract: 200 words

ABSTRACT (200 words)

Objective: To assess the evidence on the presence of antibodies that are cross-reactive with SARS-CoV-2 antigens in pre-pandemic samples from African populations.

Methods: We performed a systematic review and meta-analysis of studies evaluating pre-pandemic African samples for anti-SARS-CoV-2 cross-reactive antibodies using pre-set assay-specific thresholds for seropositivity.

Results: 24 articles with 146 datasets were eligible, including 3,194 positives among 27,269 measurements (11.7%) with large between-dataset heterogeneity. Positivity was similar for anti-N and anti-S antibodies (14% and 11%, respectively) and it was higher for anti-S1 (23%) and lower for anti-RBD antibodies (7%). Positivity was non-significantly higher for IgM than for IgG antibodies. Positivity was seen prominently in countries where malaria transmission occurs throughout and in datasets enriched in malaria cases (14%, 95% CI, 13-17%) versus 2%, 95% CI 1-3% in other datasets). Substantial SARS-CoV-2 reactivity was seen in high malaria burden with or without high dengue burden (15% and 12%, respectively), and not without high malaria burden (2% and 0%, respectively). Lower SARS-CoV-2 cross-reactivity was seen in countries and cohorts of high HIV seroprevalence, but this association was not validated in individual samples.

Conclusions: Pre-pandemic samples from Africa show high levels of anti-SARS-CoV-2 seropositivity. Levels of cross-reactivity tracks especially with malaria prevalence.

Keywords: COVID-19, SARS-CoV-2, malaria, cross-reactivity, pre-pandemic, seroprevalence.

INTRODUCTION

The number of recorded COVID-19 deaths in Africa during the pandemic has been very small compared with other continents. A wide range of explanations has been proposed,[1] ranging from favorable population features (very young, low obesity rates) to undercounted deaths in Africa due to limited testing.[2] A most tantalizing hypothesis has been that pre-existing immunity to SARS-CoV-2 may account for less severe outcomes. Impetus for this hypothesis has been provided by several studies documenting cross-reactive humoral immunity to SARS-CoV-2 in African samples that predate the pandemic years.[3-12] This pattern has typically not been seen in populations from highly developed countries. Cross-reactivity to endemic coronaviruses may not suffice to explain this phenomenon, because endemic coronaviruses are practically ubiquitously distributed across all continents. There have been speculations whether cross-reactive antibodies reflect prior exposure to other infectious pathogens widespread in Africa like *Plasmodium*, dengue and HIV.

African studies on this matter have used very diverse sources of pre-pandemic samples in various countries. They have also used different antibody assays for various antibody types and SARS-CoV-2 antigenic targets. There are conflicting hints on whether cross-reactivity may pertain mostly to specific antibody types and antigenic targets. Some studies have also explored different correlations between the presence of anti-SARS-CoV-2 cross-reactivity and markers of various other pathogens. While each of them offers a limited picture, a systematic examination may offer some more concrete insights. Important questions to answer are: how frequently are SARS-CoV-2 cross-reactive antibodies detected in pre-pandemic African samples, how much heterogeneity exists on their prevalence, and whether heterogeneity may be explained by the assay and type of antibodies assessed, each country's endemicity for *Plasmodium* and dengue,

and HIV infection rates. This systematic review and meta-analysis aimed to answer these questions.

METHODS

Protocol

The protocol was preregistered in OSF (https://osf.io/f5g76/).

Eligible studies

Eligible studies were those that evaluated samples collected in African countries before December 2019, i.e. in the pre-pandemic period, for humoral responses to SARS-CoV-2 in blood (plasma or serum). Any type of antibody and any type of assay thereof was eligible. Studies were eligible if they used pre-set assay-specific thresholds of antibody titers for claiming positive results. Studies that measured antibodies in other body fluids (e.g., milk) were excluded. Studies that calibrated the assay threshold so as to make it appropriate for use in African populations by setting the specificity at a desired level were excluded; however, if these studies presented also specificity results according to an original pre-set threshold (based on previous work on other, non-African populations), the estimates of specificity based on the pre-set threshold were eligible. Similarly, studies that used assays that were previously calibrated so as to have a desirable level of specificity in African samples were excluded. Furthermore, studies that considered only pre-pandemic samples that were already screened to be negative for anti-SARS-CoV-2 antibodies based on some other SARS-CoV-2 antibody assay were excluded. For studies that included both African and other continent samples from the pre-pandemic era, only the former were eligible, and data were thus considered only if the African set could be separated. We did not consider neutralizing antibody assays, as it has been clearly shown that detected antibodies in pre-pandemic African samples typically do not have neutralizing capacity.[13,14]

Search strategies

PubMed was searched (last update April 2, 2023) with the following search string: (Nigeria OR Ethiopia OR Egypt OR Congo OR Tanzania OR South Africa OR Kenya OR Uganda OR Sudan OR Algeria OR Morocco OR Angola OR Mozambique OR Ghana OR Madagascar OR Cameroon OR Cote d'Ivoire OR Niger OR Burkina Faso OR Mali OR Malawi OR Zambia OR Senegal OR Chad OR Somalia OR Zimbabwe OR Guinea OR Rwanda OR Benin OR Burundi OR Tunisia OR South Sudan OR Togo OR Sierra Leone OR Libya OR Liberia OR Central African Republic OR Mauritania OR Eritrea OR Namibia OR Gambia OR Botswana OR Gabon OR Lesotho OR Guinea-Bissau OR Africa OR African) AND (pre-pandemic OR prepandemic OR cross-reactiv* OR seroprevalence OR negative samples OR negative controls OR (specificity AND test) OR (specificity AND antibod*)) AND (COVID-19 OR SARS-CoV-2). We also searched the reference lists of the retrieved eligible papers and searched in Google Scholar the articles that cite the retrieved eligible papers in order to identify and additional relevant eligible papers.

Data extraction

From each eligible paper, we extracted the following information: first author, publication venue, African county(ies) from which pre-pandemic samples were obtained, sample size (per country and per cohort, if many countries/cohorts were assessed), provenance of the samples and any information about the sampling process, time periods when they were collected, age information; type of SARS-COV-2 assays and of antibodies measured, including manufacturer or laboratory of provenance, type of antibody (IgG, IgM, IgA, combinations, all antibodies) and antigenic targets (spike S, S1 subunit, S2 subunit, nucleocapsid N, receptor binding domain RBD, receptor binding motif RBM, other); number and percentage of positive

samples for each antibody/assay assessed among total assessed; any borderline readings; any additional information on measurements of indicators of other infectious diseases (*Plasmodium* parasitemia, *Plasmodium* antigens, HIV positivity status, dengue, other) with the potential to generate 2x2 tables for SARS-CoV-2 antibodies against these indicators; and any additional information on relationships between SARS-CoV-2 antibodies and other factors assessed by the authors.

Data extraction was performed in duplicate by two independent assessors who then compared notes and solved discrepancies with discussion.

Risk of bias assessment

Eligible articles were assessed using the Joanna Briggs risk of bias tool for prevalence studies that includes 9 assessment items.[15] Assessment was done by one assessor.

Meta-analysis

Available data on percentage of positive samples with different assays and antigenic targets were combined with meta-analysis using a random effects model.[16] Heterogeneity was assessed with the chi-square-based Q test and with the I^2 statistic.[17] Borderline readings were considered negative (as also done by the original individual study authors).

Subgroup analyses were performed according to type of antibody (IgG, IgM, IgA, combinations, all antibodies). Moreover, when different types of antibody (e.g. IgG and IgM) had been assessed with the same assay platform in the same samples, the matched McNemar odds ratio was calculated.

We also performed subgroup analyses according to country of origin of the samples, classifying countries according to endemicity/burden for malaria, dengue, and rates of HIV infection. For malaria, we used the CDC map of malaria distribution[18] separating countries

where malaria transmission occurs throughout versus those where no transmission occurs or transmission occurs only in some places. For dengue, we used the Global Consensus 2013 map[19] separating countries where dengue is present or likely from countries where dengue in uncertain, unlikely or absent. For HIV, we considered the eight countries with highest HIV positivity rates (>10% according to CIA fact book and UNAIDS AIDS info,[20] i.e. Botswana, Lesotho, Mozambique, Namibia, South Africa, Eswatini, Zambia, and Zimbabwe) versus others. Studies where sampling explicitly aimed to recruit participants based on or heavily enriched in *Plasmodium*, dengue, or HIV infections were considered in the groups with high burden, even if they come from countries without high burden.

Finally, whenever data were available to generate 2x2 tables for the presence of anti-SARS-CoV-2 antibodies and other infectious disease markers or other factors potentially associated with such antibodies, random effects meta-analyses were also performed for the odds ratios of each probed association across the eligible studies that presented sufficient data.

Meta-analyses were conducted in STATA SE 15. P-values were considered statistically significant for $P<0.005$ and suggestive for values between 0.005 and 0.05.[21]

RESULTS

Eligible studies

We screened 2,203 published items (Figure 1) of which 45 were screened in full text. 24 were excluded and 21 were eligible, while 3 more eligible studies (one article, one thesis and one preprint) were retrieved from cited/citation searches for a total of 24 eligible studies.[3-14, 22-33] Studies screened in-depth and excluded are shown in Supplementary References along with reasons for exclusion. Supplementary Table 1 shows the results of the risk of bias assessment.

With one exception participants came from Sub-Saharan Africa (Table 1). Dataset sample sizes ranged from 19 to 1,077 (sum=27,269). There was also wide variation in the settings of sample collection and eligibility criteria. Six studies included independent cohorts from more than one country and two studies included different cohorts from the same country. Most samples were selected between 2016 and 2019, but 9 cohorts had earlier samples (earliest, 1999). Most cohorts had collected samples from both children and adults, but several included only adults and 2 included only children (Table 1).

There was a large variety of assays used, but most studies used assays of IgG (Table 2). Most studies assessed antibodies against both spike and nucleocapsid antigenic targets, but antigenic targets varied across studies (Table 2). In-depth assessments for associations with indicators of infectious pathogens were sparse.

Positivity for SARS-CoV-2 antibodies

Supplementary Table 2 shows the data on the presence of positive results for the assessed SARS-CoV-2 antibodies and variables considered in the subgroup analyses. Overall, 146 datasets among pre-pandemic samples were available for analysis with crude total of 3,194 positives among 27,269 measurements (11.7%). When all 146 datasets were considered in meta-analysis, there was large between-dataset heterogeneity ($p<0.001$, $I^2=96.5\%$) with summary random effects positivity 11% (95% CI, 10-12%).

Meta-analysis of positivity per antigenic target and antibody type

As shown in Table 3, summary positivity was similar for anti-N (14%) and anti-S (11%) antibodies. However, when more specific epitopes within spike were considered, summary positivity was higher for anti-S1 (23%, 95% CI, 19-28%) and lower for anti-RBD antibodies (7%, 95% CI, 5-8%). Lowest positivity was seen for antibodies using both N and S (or subtype)

targets (6%, 95% CI, 4-8%). Positivity was non-significantly higher for IgM (summary 14%) than for IgG (summary 11%) antibodies. There was very large between-dataset heterogeneity in all summary estimates ($p<0.001$), so they should be seen with great caution.

Paired comparisons of antibody types

In 17 datasets, both IgG and IgM had been measured with the same type of assays and antigenic target on the same samples. For 15/17, data on paired measurements in each sample were available (Supplementary Table 3, in another 2 small datasets had no sufficient data to calculate paired odds ratios). The results were very heterogeneous making their synthesis precarious: in 7 datasets the 95% confidence intervals of the paired odds ratio excluded the null, but in 4 datasets, the samples positive only by IgM were more than the samples positive only by IgG, while the opposite situation was seen for 3 datasets.

Subgroup analyses for malaria, dengue, and HIV

As shown in Table 3, anti-SARS-CoV-2 positivity was very different according to malaria status. It was seen prominently in countries where malaria transmission occurs throughout and in datasets enriched in malaria cases (summary estimate 14%, 95% CI, 13-15%), but was almost absent in other datasets (summary estimate 2%, 95% CI, 1-3%). There was still very large between-study heterogeneity in the former group, and less heterogeneity in the latter. Among the 30 datasets in the latter group, positivity was always 0% or very low (=<8%) except for one dataset from Tanzania which is a country where malaria transmission does occur throughout in altitudes below 1800 meters.

A higher proportion of anti-SARS-CoV-2 positivity was seen in high dengue burden datasets than others (summary estimates 12% versus 9%), but large between-dataset

heterogeneity existed within each group ($p<0.001$). All the low-dengue datasets with non-negligible positivity came from studies in populations with high levels of malaria.

When data were analyzed in 4 subgroups according to both malaria and dengue burden (Figure 2), seropositivity was similar in settings with high malaria burden regardless of whether they had high or low dengue burden (15% and 12%, respectively). Conversely, there was low or no seropositivity in settings with low malaria burden, regardless of whether they had high or low dengue burden (2% and 0%, respectively).

An inverse association was seen with HIV infection, with lower proportions of anti-SARS-CoV-2 antibody positivity in countries with high HIV transmission or datasets with >10% of the sample being HIV-positive than in datasets with lower HIV rates (summary positivity 6% versus 14%). There was large between-dataset heterogeneity ($p<0.001$) within each group.

Other assessed associations with infectious disease indicators

One study[11] provided 2x2 tabular data on positivity with 4 different anti-SARS-CoV-2 IgG assays in subgroups defined by the presence of *Plasmodium* parasitemia. Combining the 4 evaluations (Supplementary Table 4), the summary odds ratio was 1.84 (95% CI, 0.90-3.78, I^2=29.2%). Two studies[9,12] included data from 3 cohorts where presence of anti-SARS-CoV-2 antibodies was given per HIV serostatus (Supplementary Table 5); the summary odds ratio was 0.97 (0.55-1.70, I^2=0%). Data were limited or not presented in sufficient detail for formal meta-analysis for other infectious disease indicators.

DISCUSSION

The present meta-analysis includes data from 24 studies with 146 datasets and more than 27,000 measurements of anti-SARS-CoV-2 antibodies in pre-pandemic samples from Africa. On average, approximately 1 of 9 samples tested positive for anti-SARS-CoV-2 antibodies, but there

was extensive heterogeneity across studies and datasets, with several studies finding 0% positivity and some others exceeding 80%. Cross-reactivity was slightly more common with IgM rather than IgG measurements on average, but prominence of IgM versus IgG signals varied greatly across datasets. While spike and nucleocapsid antibodies overall did not have substantial differences in positivity on average, subtypes within spike had different profiles. Stark differences were seen according to malaria burden. Anti-SARS-CoV-2 cross-reactivity was seen almost entirely in samples from areas with malaria transmission throughout and/or enriched in malaria cases. A more modest association was seen for dengue. However, malaria and dengue endemicity largely overlap, and samples coming from high dengue but low malaria burden settings had negligible positivity. Finally, HIV was associated with lower frequency of anti-SARS-CoV-2 antibodies, but this may have reflected simply the inverse geographical localization of HIV and malaria burden in Africa.

The composite picture is consistent with the possibility that the observed pre-pandemic seropositivity to SARS-CoV-2 in Africa may reflect to a considerable extent cross-reactive response to malaria. Lapidus et al. suggest that this immune response is more common and more intense in acute and recent malaria.[14] They have also attributed that to a good extent the cross-reactivity may reflect antibodies targeting sialic acid moieties on the S1 fragment, and cross-reactivity is effectively reduced when sialic acid is cleaved from the assay target.[14] The large between-dataset heterogeneity among studies with high malaria burden may reflect both the type of assay used as well as the large variability in the magnitude of the malaria burden: some datasets in the meta-analysis included exclusively acute malaria, others were heavily enriched in malaria cases, and others simply came from areas with substantial malaria burden. Cross-reactivity with dengue is also possible, but most areas in Africa that have high dengue burden

have also high malaria burden. The meta-analysis of datasets from settings with high dengue but low malaria shows negligible anti-SARS-CoV-2 positivity.

Anti-SARS-CoV-2 humoral cross-reactivity in pre-pandemic samples has generally not been observed in European and USA studies. Data from countries outside Africa also suggest that malaria rather than dengue has a strong association with the presence of antibodies that are cross-reactive against SARS-CoV-2. Manning et al.[34] found 14% cross-reactive positivity among 528 samples of patients with malaria from Cambodia. Data for dengue are mixed. One study in Taiwan[35] found higher optical density anti-S1 RBD activity in archival dengue samples than in controls, but the optical density values were still low. Another study[36] found some IgM and IgA rather IgG false-positivity for SARS-CoV-2 in febrile illness from dengue in Thailand, but the false-positivity tended to be even more frequent for febrile illness from non-dengue cases (including apparently malaria). In a study with samples from Puerto Rico and USA,[37] dengue did not induce cross-reactive antibodies to SARS-CoV-2 and the same was true in dengue samples from Indonesia,[38] Colombia[39] and travel clinics.[40] Conversely, 5 of 17 archival dengue samples from India[41] had cross-reactive antibodies to SARS-CoV-2 and another study[42] found 22% cross-reactivity in samples from an Israel center (unspecified country of provenance); however, it is unknown whether any positive samples could be from patients who also had a history of malaria. SARS-CoV-2 infection has been described to frequently produce cross-reactive antibody activity to dengue,[38,39,42] but not seen in all studies.[37] Anti-SARS-CoV-2 antibodies may also have a protective role for dengue[35] and, interestingly, reported dengue cases and deaths declined in 2020-2022 after a peak in 2019.[43] In-silico analysis shows possible similarities between SARS-CoV-2 epitopes in the HR2 domain of the spike protein and the dengue envelope protein,[42] but

the evidence is again stronger for malaria, where cross-reactive antibodies specifically recognized the sialic acid moiety on N-linked glycans of the Spike protein.[14]

The clinical and public health importance of pre-existing humoral cross-reactivity remains a tantalizing question. The evidence is mixed. Some studies have suggested that the detected antibodies test negative in neutralization assays.[13,14] Conversely, Li et al.[32] found neutralizing responses in some pre-pandemic samples; neutralizing and binding activities did not seem to correlate. Stronger evidence for neutralizing activity was obtained by Nyagwange et al.[44] who analyzed pre-pandemic samples from coastal Kenya and found clear evidence of neutralization for pseudotyped reference SARS-CoV-2 with a mean infective dose 50 of 1:251, which is still within predicted protection levels. In the same study, the pre-pandemic naso-oropharyngeal fluid also neutralized pseudo-SARS-CoV-2 at a mean infective dose 50 of 1:5.9.

These cross-reactive antibodies they may be a marker of a much broader immune response that includes both humoral and cellular features. Pre-existing T-cell immunity and its potential role in ameliorating clinical course in SARS-CoV-2 infection is another debated issue.[45] It would be useful to assess pre-pandemic samples with anti-SARS-CoV-2 antibodies for a broad spectrum of immune functionalities. Non-humoral immunity elements appear even more frequent than the detected humoral immunity, since humoral immunity tends to wane relatively rapidly.[46] Cross-reactive CD4+ and CD8+ T-cell responses to SARS-CoV-2 were documented in 90% of pre-pandemic samples from Uganda,[47] but only 10-50% in pre-pandemic samples from the USA or Europe.[48-50] Cross-reactive T-cell responses can be derived from both homologous pathogens (other coronaviruses, including the widely endemic and globally-distributed coronaviruses) and non-homologous ones (e.g. CMV).[51]

The geographical pattern of the documented impact of COVID-19 in Africa is intriguingly well aligned with the geographical pattern of detected pre-pandemic humoral cross-reactivity. Recorded COVID-19 deaths have been far higher in South Africa (high HIV, relatively low malaria burden) and in northern African countries (low malaria burden) than in other countries in sub-Saharan Africa (high malaria burden). These areas are unlikely to have differed in prior exposure to endemic coronaviruses. Differences in the extent of under-ascertainment of COVID-19 deaths, demographic and lifestyle differences (older populations in northern Africa, high levels of obesity in South Africa) may also partly underlie these differences. However, a contribution of pre-existing immunity remains also an additional possibility. Pre-existing immunity has also been raised as a possible important contributing factor to relatively low fatalities in East Asia;[52] many areas in East Asia also have substantial malaria burden. Conversely, recent dengue outbreaks did not seem to protect from COVID-19 fatalities; the highest number of dengue cases and deaths in 2019 was seen in Brazil,[43] a country that suffered high COVID-19 fatalities.

Our work has limitations. First, the examined studies mostly used convenient samples available from pre-pandemic efforts not tailored specifically to answer questions posed by the pandemic. For many samples, information about their provenance and features was limited. Second, several analyses have ecological designs, e.g. when countries were assigned to high or low burden groups for specific pathogens. The observed associations may not necessarily hold true also at the level of analyses profiling prior infection in single individual samples. Nevertheless, the more limited individual level data available also agree with the main findings regarding malaria.[53] Conversely, ecological associations with HIV may be spurious and some additional data suggest no association between the strength of anti-SARS-CoV-2 and anti-HIV

responses.[32] Third, some analyses include datasets which represent the same samples tested with different assays, therefore they are not entirely independent. However, the major differences observed (e.g. with malaria) remain strong even if only one dataset is selected per study/cohort (not shown). Fourth, it is uncertain if due to publication bias more studies that found no seropositivity in pre-pandemic African samples may have remained unpublished compared with studies that found high positivity. Fifth, the assays used were very diverse and the technical competence of their performance by different teams cannot be validated independently. This may explain also part of the observed large between-dataset heterogeneity. However, errors would tend to weaken observed associations, if anything, through non-differential mis-classification.

Acknowledging these caveats, our meta-analysis provides strong evidence for pre-pandemic cross-reactive humoral immunity to SARS-CoV-2 in Africa, closing tracking with malaria. Further studies of broader immunological profiles involved and of the public health implications are necessary.

Contributors

Both authors conceived the original idea, wrote the protocol, extracted data, run and interpreted analyses, wrote and revised the paper and approved the final version.

Funding

None

Declaration of interests

No conflicts of interest.

Data sharing statement

All data are in the manuscript and its supplements

Ethical approval

Not applicable

REFERENCES

1. Adams J, MacKenzie MJ, Amegah AK, et al. The conundrum of low COVID-19 mortality burden in sub-Saharan Africa: myth or reality?. Glob Health Sci Pract. 2021;9(3):433-443.
2. Ioannidis JPA. Over- and under-estimation of COVID-19 deaths. Eur J Epidemiol. 2021 Jun;36(6):581-588.
3. Pedersen J, Koumakpayi IH, Babuadze G, et al. Cross-reactive immunity against SARS-CoV-2 N protein in Central and West Africa precedes the COVID-19 pandemic. Sci Rep. 2022 Jul 28;12(1):12962.
4. Traoré A, Guindo MA, Konaté D, et al. Seroreactivity of the Severe Acute Respiratory Syndrome Coronavirus 2 Recombinant S Protein, Receptor-Binding Domain, and Its Receptor-Binding Motif in COVID-19 Patients and Their Cross-Reactivity With Pre-COVID-19 Samples From Malaria-Endemic Areas. Front Immunol. 2022 Apr 27;13:856033.
5. Iriemenam NC, Ige FA, Greby SM, Okunoye OO, Uwandu M, Aniedobe M, Nwaiwu SO, Mba N, Okoli M, William NE, Ehoche A, Mpamugo A, Mitchell A, Stafford KA, Thomas AN, Olaleye T, Akinmulero OO, Agala NP, Abubakar AG, Owens A, Gwyn SE, Rogier E, Udhayakumar V, Steinhardt LC, Martin DL, Okoye MI, Audu R. Comparison of one single-antigen assay and three multi-antigen SARS-CoV-2 IgG assays in Nigeria. J Clin Virol Plus. 2023 Feb;3(1):100139.
6. Borrega R, Nelson DKS, Koval AP, et al. Cross-Reactive Antibodies to SARS-CoV-2 and MERS-CoV in Pre-COVID-19 Blood Samples from Sierra Leoneans. Viruses. 2021 Nov 21;13(11):2325.

7. Ige F, Hamada Y, Steinhardt L, et al. Validation of Commercial SARS-CoV-2 Immunoassays in a Nigerian Population. Microbiol Spectr. 2021 Oct 31;9(2):e0068021.
8. Woodford J, Sagara I, Dicko A, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Seroassay Performance and Optimization in a Population With High Background Reactivity in Mali. J Infect Dis. 2021 Dec 15;224(12):2001-2009.
9. Baker OR, Grabowski MK, Galiwango RM, et al. Differential Performance of CoronaCHEK SARS-CoV-2 Lateral Flow Antibody Assay by Geographic Origin of Samples. J Clin Microbiol. 2021 Jun 18;59(7):e0083721.
10. Steinhardt LC, Ige F, Iriemenam NC, et al. Cross-Reactivity of Two SARS-CoV-2 Serological Assays in a Setting Where Malaria Is Endemic. J Clin Microbiol. 2021 Jun 18;59(7):e0051421.
11. Emmerich P, Murawski C, Ehmen C, et al. Limited specificity of commercially available SARS-CoV-2 IgG ELISAs in serum samples of African origin. Trop Med Int Health. 2021 Jun;26(6):621-631.
12. Tso FY, Lidenge SJ, Peña PB, et al. High prevalence of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa. Int J Infect Dis. 2021 Jan;102:577-583.
13. Yansouni CP, Papenburg J, Cheng MP, et al. Specificity of SARS-CoV-2 Antibody Detection Assays against S and N Proteins among Pre-COVID-19 Sera from Patients with Protozoan and Helminth Parasitic Infections. J Clin Microbiol. 2022 Jan 19;60(1):e0171721.

14. Lapidus S, Liu F, Casanovas-Massana A, Dai Y, Huck JD, Lucas C, Klein J, et al. Plasmodium infection is associated with cross-reactive antibodies to carbohydrate epitopes on the SARS-CoV-2 spike protein. Sci Rep. 2022;12(1):22175.
15. Munn Z, Moola S, Riitano D, Lisy K. The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence. Int J Heal Policy Manag. 2014;3(3):123–8.
16. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997 Nov 1;127(9):820-6.
17. Ioannidis JP. Interpretation of tests of heterogeneity and bias in meta-analysis. J Eval Clin Pract. 2008 Oct;14(5):951-7.
18. CDC. Malaria distribution, in: https://www.cdc.gov/malaria/about/distribution.html, last accessed September 13, 2022.
19. Dengue Global Consensus 2013 map, in https://www.healthmap.org/dengue/en/, last accessed September 13, 2022.
20. AIDS adult prevalence, in https://en.wikipedia.org/wiki/List_of_countries_by_HIV/AIDS_adult_prevalence_rate, last accessed September 13, 2022.
21. Benjamin DJ, Berger JO, Johannesson M, et al. Redefine statistical significance. Nat Hum Behav. 2018 Jan;2(1):6-10.
22. Yadouleton A, Sander AL, Moreira-Soto A, et al. Limited Specificity of Serologic Tests for SARS-CoV-2 Antibody Detection, Benin. Emerg Infect Dis. 2021 Jan;27(1):233–7.

23. Diagne CT, Ndiaye O, Talla C, et al. Cross-Reactivity of SARS-CoV-2 Laboratory Diagnostics to Endemic Diseases in Africa: A Diagnostic Accuracy Study. Available at SSRN: http://dx.doi.org/10.2139/ssrn.3916756
24. Mveang Nzoghe A, Essone PN, Leboueny M, et al. Evidence and implications of pre-existing humoral cross-reactive immunity to SARS-CoV-2. Immun Inflamm Dis. 2021 Mar;9(1):128-133.
25. Souris M, Tshilolo L, Parzy D, Lobaloba Ingoba L, Ntoumi F, Kamgaing R, Ndour M, Mbongi D, Phoba B, Tshilolo MA, Mbungu R, Sosso MS, Fainguem N, Ndiaye Dieye T, Sylla M, Morand P, Gonzalez JP. Pre-Pandemic cross-reactive immunity against SARS-CoV-2 among Central and West African populations. Viruses. 2022 Oct 14;14(10):2259.
26. Lobaloba Ingoba L, Djontu JC, Mfoutou Mapanguy CC, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in a population living in Bomassa village, Republic of Congo. IJID Reg. 2022 Mar;2:130-136.
27. Gdoura M, Halouani H, Sahli D, Mrad M, Chamsa W, Mabrouk M, Hogga N, Ben-Salem K, Triki H. SARS-CoV-2 serology: utility and limits of different antigen-based tests through the evaluation and the comparison of four commercial tests. Biomedicines. 2022 Dec 1;10(12):3106.
28. Gebrecherkos T, Kiros YK, Challa F, et al. Longitudinal profile of antibody response to SARS-CoV-2 in patients with COVID-19 in a setting from Sub-Saharan Africa: A prospective longitudinal study. PLoS One. 2022 Mar 23;17(3):e0263627.
29. Gelanew T, Seyoum B, Mulu A, et al. High seroprevalence of anti-SARS-CoV-2 antibodies among Ethiopian healthcare workers. BMC Infect Dis. 2022 Mar 16;22(1):261.

30. Mboumba Bouassa RS, Péré H, Tonen-Wolyec S, et al. Unexpected high frequency of unspecific reactivities by testing pre-epidemic blood specimens from Europe and Africa with SARS-CoV-2 IgG-IgM antibody rapid tests points to IgM as the Achilles heel. J Med Virol. 2021 Apr;93(4):2196-2203.
31. Vanroye F, Bossche DVD, Brosius I, Tack B, Esbroeck MV, Jacobs J. COVID-19 Antibody Detecting Rapid Diagnostic Tests Show High Cross-Reactivity When Challenged with Pre-Pandemic Malaria, Schistosomiasis and Dengue Samples. Diagnostics (Basel). 2021 Jun 25;11(7):1163.
32. Li Y, Merbah M, Wollen-Roberts S, Beckman B, Mdluli T, Swafford I, Mayer SV, King J, Corbitt C, Currier JR, Liu H, Esber A, Pinyakorn S, Parikh A, Francisco LV, Phanuphak N, Maswai J, Owuoth J, Kibuuka H, Iroezindu M, Bahemana E, Vasan S, Ake JA, Modjarrad K, Gromowski G, Paquin-Proulx D, Rolland M. Coronavirus Antibody Responses before COVID-19 Pandemic, Africa and Thailand. Emerg Infect Dis. 2022 Nov;28(11):2214-2225.
33. Naidoo M. Evaluation of Two SARS-CoV-2 Immunoassays, thesis NDXMIC018, submitted to the University of Cape Town, 2022, in: https://open.uct.ac.za/handle/11427/37603, last accessed April 4, 2023.
34. Manning J, Zaidi I, Lon C, et al. SARS-CoV-2 cross-reactivity in prepandemic serum from rural malaria-infected persons, Cambodia. Emerg Infect Dis. 2022;28:440–4.
35. Cheng YL, Chao CH, Lai YC, et al. Antibodies against the SARS-CoV-2 S1-RBD cross-react with dengue virus and hinder dengue pathogenesis. Front Immunol. 2022 Aug 15;13:941923.

36. Luvira V, Leaungwutiwong P, Thipporrnchai N, et al. False Positivity of Anti-SARS-CoV-2 Antibodies in Patients with Acute Tropical Diseases in Thailand. Trop Med Infect Dis. 2022 Jul 12;7(7):132.
37. Munoz-Jordan J, Cardona J, Beltrán M, et al. Evaluation of Serologic Cross-Reactivity Between Dengue Virus and SARS-CoV-2 in Patients with Acute Febrile Illness - United States and Puerto Rico, April 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2022 Mar 11;71(10):375-377.
38. Santoso MS, Masyeni S, Haryanto S, et al. Assessment of dengue and COVID-19 antibody rapid diagnostic tests cross-reactivity in Indonesia. Virol J. 2021 Mar 11;18(1):54. doi: 10.1186/s12985-021-01522-2.
39. Faccini-Martínez ÁA, Rivero R, Garay E, et al. Serological cross-reactivity using a SARS-CoV-2 ELISA test in acute Zika virus infection, Colombia. Int J Infect Dis. 2020 Dec;101:191-193. doi: 10.1016/j.ijid.2020.09.1451. Epub
40. Spinicci M, Bartoloni A, Mantella A, Zammarchi L, Rossolini GM, Antonelli A. Low risk of serological cross-reactivity between dengue and COVID-19. Mem Inst Oswaldo Cruz. 2020;115:e200225.
41. Nath H, Mallick A, Roy S, et al. Archived dengue serum samples produced false-positive results in SARS-CoV-2 lateral flow-based rapid antibody tests. J Med Microbiol. 2021 Jun;70(6):001369. doi: 10.1099/jmm.0.001369.
42. Lustig Y, Keler S, Kolodny R, et al. Potential Antigenic Cross-reactivity Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Dengue Viruses. Clin Infect Dis. 2021 Oct 5;73(7):e2444-e2449. doi: 10.1093/cid/ciaa1207.
43. WHO. Dengue and severe dengue, update Jan 10, 2022.

44. Nyagwange J, Kutima B, Mwai K, Karanja HK, Gitonga JN, Mugo D, Sein Y, Wright D, Omuoyo DO, Nyiro JU, Tuju J, Nokes DJ, Agweyu A, Bejon P, Ochola-Oyier LI, Scott JAG, Lambe T, Nduati E, Agoti C, Warimwe GM. Serum immunoglobulin G and mucosal immunoglobulin A antibodies from prepandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro. Int J Infect Dis. 2023 Feb;127:11-16.
45. Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020 Aug;584(7821):457-462.
46. Goldberg Y, Mandel M, Bar-On YM, et al. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2. N Engl J Med. 2022 Jun 9;386(23):2201-2212.
47. Namuniina A, Muyanja ES, Biribawa VM, Okech BA, Ssemaganda A, Price MA, et al. High proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell responses. medRxiv [Preprint]. 2023 Jan 20:2023.01.16.23284626. doi: 10.1101/2023.01.16.23284626.
48. Mateus J, Grifoni A, Tarke A, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in 284 unexposed humans. Science; 2020;370(6512).
49. Braun J, Loyal L, Frentsch M, et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature; 2020; 587(7833):270–274.
50. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell; 2020; 181(7):1489-1501.e15

51. Pothast CR, Dijkland RC, Thaler M, Hagedoorn RS, Kester MGD, Wouters AK, et al. SARS-CoV-2-specific CD4+ and CD8+ T cell responses can originate from cross-reactive CMV-specific T cells. Elife. 2022 Nov 21;11:e82050.
52. Bhattacharya J, Magness P, Kulldorff M. Understanding the exceptional pre-vaccination era East Asian COVID-19 outcomes. Adv Biol Regul 2022;86:100916.
53. Benabdessalem C, Hamouda WB, Marzouki S, Faye R, Mbow AA, Diouf B, Ndiaye O, Dia N, Faye O, Sall AA, Diagne CT, Amellal H, Ezzikouri S, Mioramalala DJN, Randrianarisaona F, Trabelsi K, Boumaiza M, Hamouda SB, Ouni R, Bchiri S, Chaaban A, Gdoura M, Gorgi Y, Sfar I, Yalaoui S, Khelil JB, Hamzaoui A, Abdallah M, Cherif Y, Petres S, Mok CKP, Escriou N, Quesney S, Dellagi K, Schoenhals M, Sarih M, Vigan-Womas I, Bettaieb J, Rourou S, Barbouche MR, Ahmed MB. Development and comparative evaluation of SARS-CoV-2 S-RBD and N based ELISA tests in various African endemic settings. Diagn Microbiol Infect Dis. 2023 Apr;105(4):115903.

Figure 1: Flow chart for searches and eligible studies



Figure 2: Meta-analysis of positivity rates for anti-SARS-COV-2 antibodies in pre-pandemic samples for studies from countries or settings with (A) high malaria burden and high dengue burden, (B) high malaria burden and low dengue burden, (C) low malaria burden and high dengue burden, and (D) low malaria burden and low dengue burden

High Malaria and High Dengue



High Malaria and Low Dengue




Low Malaria and High Dengue
Study
ES (95% CI)
% Weight
Tso (Tanzania) 0.17 (0.10, 0.26) 1.99
Tso (Tanzania) 0.03 (0.01, 0.08) 4.39
Emmerich (Magadascar) 0.02 (0.00, 0.05) 5.33
Emmerich (Magadascar) 0.01 (0.00, 0.04) 5.59
Emmerich (Magadascar) 0.07 (0.03, 0.11) 3.94
Emmerich (Magadascar) 0.01 (0.00, 0.03) 5.88
Gelanew (Ethiopia) 0.08 (0.06, 0.12) 4.69
Gebrecherkos (Ethiopia) 0.00 (0.00, 0.07) 4.78
Gebrecherkos (Ethiopia) 0.00 (0.00, 0.07) 4.78
Gebrecherkos (Ethiopia) 0.00 (0.00, 0.07) 4.78
Gebrecherkos (Ethiopia) 0.00 (0.00, 0.07) 4.78
Gebrecherkos (Ethiopia) 0.00 (0.00, 0.07) 4.78
Gebrecherkos (Ethiopia) 0.00 (0.00, 0.07) 4.78
Gebrecherkos (Ethiopia) 0.00 (0.00, 0.07) 4.78
Gebrecherkos (Ethiopia) 0.00 (0.00, 0.07) 4.78
Gebrecherkos (Ethiopia) 0.00 (0.00, 0.07) 4.78
Gebrecherkos (Ethiopia) 0.04 (0.00, 0.14) 2.82
Gebrecherkos (Ethiopia) 0.00 (0.00, 0.07) 4.78
Gebrecherkos (Ethiopia) 0.04 (0.00, 0.14) 2.82
Gebrecherkos (Ethiopia) 0.00 (0.00, 0.07) 4.78
Li (Tanzania) 0.06 (0.03, 0.09) 4.59
Li (Kenya) 0.07 (0.05, 0.09) 5.37
Overall (I^2 = 79.44%, p = 0.00) 0.02 (0.01, 0.03) 100.00
.25
.5
.75
1
Proportion SARS-CoV-2 Cross-Reactivity


Low Malaria and Low Dengue
Study
ES (95% CI)
%
Weight
Gdoura (Tunisia)
0.06 (0.02, 0.12)
2.22
Gdoura (Tunisia)
0.00 (0.00, 0.03)
15.25
Gdoura (Tunisia)
0.03 (0.01, 0.07)
4.56
Gdoura (Tunisia)
0.04 (0.01, 0.10)
2.97
Gdoura (Tunisia)
0.00 (0.00, 0.03)
15.25
Gdoura (Tunisia)
0.00 (0.00, 0.03)
15.25
Naidoo (South Africa)
0.00 (0.00, 0.02)
22.93
Naidoo (South Africa)
0.00 (0.00, 0.02)
21.55
Overall (I^2 = 53.32%, p = 0.04)
0.00 (-0.00, 0.01)
100.00
.25
.5
.75
1
Proportion SARS-CoV-2 Cross-Reactivity

Table 1. Characteristics of eligible studies

Author	Country	Sample size	Provenance of the samples and sampling process	Time period of sample collection	Age in years (median)
Pedersen	Gabon	146	Unclear	Oct 2019	18-50
	Senegal	150	Unclear	Jan 2017-May 2018	65% <18
Borrega	Sierra Leone	120	Lassa and Ebola survivors and their contacts	Sept 2016-April 2019	8-60 (31)
Tso	Tanzania	105	Blood donors, 6.7% HIV-positive	Mar 2019-May 2019	≥18
	Zambia	99	Enriched in HIV-positive (43.4%)	2017- early 2019	≥18
Emmerich	Magadascar	167	Pregnant women	2010	20-30 (23)
	Ghana	150	Children	2014-2015	3-7 (6)
	Ghana	133	Teens and adults	1999	16-45 (22)
	Nigeria	150	Adults	2018	30-58 (41)
Yadouleton	Benin	60	Acute febrile illness, tested for hemorrhagic fever surveillance	Oct 2019 – Nov 2019	12-65 (28)
Nzoghe	Gabon	135	Healthy healthcare worker volunteers	2014	14-80 (38)
Woodford	Mali	312	Urban healthy adults	Jan 2017	≥18
			Rural healthy adults	May 2019	≥18

			Rural women of childbearing age	May 2019	≥18
			Rural all ages	May 2018	All ages
Baker	Uganda	1077	Rakai Community Cohort Study (543 febrile within one month, 534 non-febrile matched for age and gender)	2011-2013	18-54 (30)
Souris	DR Congo	190	Healthy subjects (hospital staff and volunteers) and young sickle-cell disease patients	2019	Any age
	DR Congo	383	Biobank from Plasmodium study in Kinshasa	2014 – 2015	Any age
	Cameroon	383	Continual health monitoring project for HIV patients	Jun 2018 – Jun 2019	Any age
	R Congo	384	Research samples from two districts	2016, 2019	Any age
Ige	Nigeria	100	50 HBV-positive (S-antigen) and 50 HIV-positive	Before Oct 2019	(35)
Traore	Mali	283	Malaria survey in Dangassa village	2019	Unclear
Ingoba	R Congo	82	Bomassa village	Jun- Jul 2019	Unclear
Diagne	Senegal	272	Biobank	Before Sept 2019	Unclear

Yansouni	Senegal	100	Clinical suspects for malaria	Before Jul 2019	Unclear
Iriemenam	Nigeria 1	100	Pre-pandemic samples of hepatitis B (n=50) or HIV (n=50) positive patients	Before Oct 2019	(35)
	Nigeria 2	200	Nigeria HIV/AIDS Indicator and Impact Survey	2018	0-60 (32)
Steinhardt	Nigeria	213	Nigeria HIV/AIDS Indicator and Impact Survey	2018	0-60
Gelanew	Ethiopia	365	Pre-pandemic sera	2012-2018	Unclear
Gebrecherkos	Ethiopia	50	Pre-pandemic samples from patients with other infections	2017	Unclear
Mboumba Bouassa	Central African Republic	100	National center of sexually transmitted diseases in Bangui, 54 HIV-seropositive, 5 HCV-positive, 35 HBsAg-positive	2000-2011	(31 mean)
Gdoura	Tunisia	119	Pre-pandemic samples	Before 2019	Unclear
Vanroye	Diverse African	195*	Travelers from Africa with malaria or schistosomiasis	2010-2018	8-61 (~40)
Lapidus	Cameroon	19	Malaria patients	Jul-Nov 2018	2-64 (26 mean)
	Senegal 1	120	Malaria patients	Jul 2019	1-74 (22 mean)
	Senegal 2	67	Malaria patients	2015-2017	5-16 (11 mean)
	Burkina	88	Malaria patients	Jul-Aug 2017	0-4 (3 mean)

	Faso 1				
	Burkina Faso 2	25	Malaria patients	Oct 2016-Feb 2017	21-43 (33)
	Ghana	45	Malaria patients	Jul 2007-June 2010	3-70 (15)
Naidoo	South Africa	316	Pre-pandemic virology serology residual samples	Before November 2019	Unclear
Li	Nigeria	361	RV466/IWARG (febrile illness study)	2014-2019	18-78 (34)
	Uganda	399	RV329/AFRICOS (mostly chronic HIV infection)	2014-2016	20-70 (40)
	Tanzania	234	RV329/AFRICOS (mostly chronic HIV infection)	2014-2016	19-74 (39)
	Kenya	653	RV329/AFRICOS (mostly chronic HIV infection)	2014-2017	19-77 (40)

*Includes 9 samples from Asia and 19 of unknown country origin; besides the n=195, the study has 25 patients with dengue, but few are from Africa, so only the malaria and schistosomiasis cases are considered here

Table 2. Immunological assays performed in the eligible studies and other pathogen indicators assessed

Author	**Antibody assays used**	**Antigenic targets**	**Other pathogen indicators assessed**
Pedersen	ELISA	S, N	
Borrega	reSARS, cutoffs defined by USA samples	N, RBD, S2	
Tso	Immunofluorescence assay, with USA control samples	N, S	HIV
Emmerich	Euroimmun, EDI, Mikrogen recomWell	S1 IgG (Euroimmun), N IgG (Euroimmun), N IgG (EDI), N IgG (Mikrogen)	*Plasmodium* parasitemia
Yadouleton	Euroimmun, INBIOS	S IgG (Euroimmun), S1 IgA (Euroimmun), S1 IgG (INBIOS), N IgG (Euroimmun)	
Nzoghe	Elecsys Roche	N all subclasses	Multiple infectious indicators assessed but presented only for SARS-C0V-2 antibody-positive samples
Woodford	Previously developed at NIH with USA samples	S, N, RBD	*Plasmodium* antigens
Baker	CoronaCHEK	Spike RBD IgG or IgM	HIV
Souris	INNOBIOCHIPS ELISA,	S1, S2, S1-RBD, S1-	

	calibrated on other human coronaviruses	NTD, N	
Ige	Euroimmun, Mologic, Abbott Architect	S1 IgG (Euroimmun), N IgG (Euroimmun), S2 or N IgG (Mologic), N IgG (Abbott)	
Traore	ELISA	S IgG, RBD IgG, RBM IgG	*Plasmodium* parasitemia, *Plasmodium* smear
Ingoba	Virotech, according to kit manufacturer	N IgG (also IgM but no data given)	
Diagne	Omega, ID-screen	N or S2 IgG (Omega), N IgG (ID-screen)	*Plasmodium* and other pathogen antibodies
Yansouni	Abbott Architect, Rapid diagnostic test (RDT)	N IgG (Abbott), N IgM (RDT), N IgG (RDT)	
Iriemenam	Tetracore, SARS2MBA, xMAP, RightSign	RBD IgG, N IgG, RBD-N hubrid IgG (Tetracore); S IgG, RBD541 IgG, RBD591 IgG, N IgG (SARS2MBA); N IgG, RBD IgG, S1 IgG (xMAP); IgG/IgM (RightSign)	
Steinhardt	Euroimmun, Abbott	N IgG (Euroimmun), N	*Plasmodium* antibodies,

	Architect	IgG (Abbott)	*Plasmodium* antigens, antibodies for filariasis, oncocherciasis, syphilis/yaws, cystocercosis, taeniasis
Gelanew	ELISA	RBD IgG	
Gebrecherkos	Canea, Cellex, VivaChek, Innovita; ECLIA Roche	N+S IgG or IgM (Cenea, Cellex, VivaChek, Innovite), N all immunoglobulin (Roche)	
Mboumba Bouassa	BIOSYNEX, SIENNA, NG-test	RBD IgG and RBD IgM (BIOSYNEX), unknown antigen IgG and unknown antigen IgM (SIENNA), unknown antigen IgG and unknown antigen IgM (NG-test)	
Gdoura	Vidas Biomerieux, Mindray, Elecsys Roche (Cobas), Access	S1 RBD IgG and S1 IgM (Vidas), S+N IgG and S+N IgG (Mindray), N all subclasses (Elecsys), S1 RBD IgG (Access)	
Vanroye	13 RDTs	N IgG or IgM (Toda, Biohit, Panbio, Boson),	

		N+S IgG or IgM (Cellex, Dynamiker, Liming Bio), RBD IgG or IgM (ZenTech), N+RBD IgG or IgM (SureScreen Diagnostics, Singuway), N+RBD+S IgG or IgM (Multi-G), S IgG or IgM (Healgen), S (Wantai)	
Lapidus	ELISA	S1 IgG, S1 IgM	All participants have had malaria (different clinical phenotypes)
Naidoo	Elecsys Roche	N all subclasses, S all subclasses	
Li	Bead-based assay	S2 IgG	HIV, *Plasmodium* smear (no statistically significant differences); several others, but only in those samples with anti-S2 reactivity

Table 3. **Summary estimates of anti-SARS-CoV-2 antibody positivity in pre-pandemic African samples**

GROUPS	Datasets	Positivity (95% CI), %	I^2
Antigenic target*			
Any N	44	14 (12-17)	96.8%
Any S	76	11 (10-13)	97.0%
S1	25	23 (19-28)	98.1%
RBD	25	7 (5-8)	95.2%
Any N +S	24	6 (4-8)	91.4%
Type of antibodies**			
IgG	105	11 (10-12)	96.3%
IgM	17	14 (9-19)	96.4%
IgG/IgM	18	12 (9-16)	97.3%
Malaria burden***			
High	116	14 (13-15)	97.0%
Low/None	30	2 (1-3)	76.7%
Dengue burden***			
High	110	12 (11-13)	96.5%
Low/None	36	9 (7-10)	96.1%
HIV burden***			
High	47	6 (5-7)	93.7%
Low/None	86	14 (12-15)	96.8%

*"Any S" includes S (n=14), S1 (n=25), S2 (n=8), RBD (n=25), RBM (n=1), NTD (n=3); "N+S" includes N+S (n=17), N+RBD (n=2), N+RBD+S (n=1), N+S2 (n=2), RBD+N (n=2); for n=2 the antigen was unknown

**not shown are IgA (n=1 dataset), all immunoglobulin subclasses (n=5 datasets) and unclear (n=1 dataset)

***see Methods for definitions of subgroups

Supplementary Table 1: Joanna Briggs risk of bias assessment

	CRITERION	Scoring of studies
1	Was the sample representative of the target population?	Not applicable (no datasets had been collected with prior anticipation to be used for this pandemic-related question)
2	Were study participants recruited in an appropriate way?	Unclear in all studies
3	Was the sample size adequate?	Yes for Woodford, Baker, Souris, Gelanew, Naidoo (N antibodies), Li (Nigeria, Uganda, Kenya) and No for the other studies or subsets (setting a threshold of having at least N=306 samples for 4% precision at 95% CI with expected proportion of positivity being 15%)
4	Were the study subjects and the setting described in detail?	No for Pedersen, Gelanew, and Gdoura and Yes for the other 15 studies if lenient about required information; most studies however did not give in-depth details
5	Was the data analysis conducted with sufficient coverage of the identified sample?	Yes for all studies, given that samples could be measured for antibodies with no/few missing measurements (although one cannot be certain of missingness at earlier stages of sampling)
6	Were objective, standard criteria used for the measurement of the condition?	Yes for all studies (based on providing definitions for positivity that are standard or defendable)
7	Was the condition measured reliably?	Unclear in all studies (it cannot be verified that

		antibody assays were performed reliably)
8	Was there appropriate statistical analysis?	Yes for all studies (if one requires only provision of positive and tested, not all studies gave confidence intervals, but these can be calculated in number of positives and of tested are given))
9	Are all important confounding factors/subgroups/differences identified and accounted for?	No for all studies, although several did explore some factors (as delineated in Table 2)
10	Were subpopulations identified using objective criteria?	Yes, for subpopulations listed in Table 2

Supplementary Table 2. Data on positivity and covariates of interest extracted

Author	Country	Antigenic targets	Antigen	Antibody	HIV high positivity	Malaria high burden	Dengue high burden	Positive	Tested
Pedersen	Gabon	S	S	IgG	No<10%	Yes	Yes	12	116
Pedersen	Gabon	N	N	IgG	No<10%	Yes	Yes	20	116
Pedersen	Senegal	S	S	IgG	No<10%	Yes	Yes	20	144
Pedersen	Senegal	N	N	IgG	No<10%	Yes	Yes	14	144
Borrega	Sierra Leone	N	N	IgG	No<10%	Yes	Yes	52	120
Borrega	Sierra Leone	RBD	RBD	IgG	No<10%	Yes	Yes	72	120
Borrega	Sierra Leone	S2	S2	IgG	No<10%	Yes	Yes	42	120
Tso	Tanzania	N	N	IgG	No<10%	No	Yes	18	105
Tso	Tanzania	S	S	IgG	No<10%	No	Yes	3	105
Tso	Zambia	N	N	IgG	Yes>10%	Yes	No	13	99
Tso	Zambia	S	S	IgG	Yes>10%	Yes	No	4	99
Emmerich	Magadascar	S1 Euroimmun	S1	IgG	No<10%	No	Yes	3	167 (0 b)
Emmerich	Magadascar	Nmod Euroimmun	N	IgG	No<10%	No	Yes	2	167 (0 b)
Emmerich	Magadascar	N EDI	N	IgG	No<10%	No	Yes	11	167 (10 b)
Emmerich	Magadascar	N Mikrogen	N	IgG	No<10%	No	Yes	1	167 (3 b)
Emmerich	Ghana 1	S1 Euroimmun	S1	IgG	No<10%	Yes	Yes	12	150 (1 b)
Emmerich	Ghana 1	Nmod Euroimmun	N	IgG	No<10%	Yes	Yes	14	150 (11 b)
Emmerich	Ghana 1	N EDI	N	IgG	No<10%	Yes	Yes	24	150 (17 b)
Emmerich	Ghana 1	N Mikrogen	N	IgG	No<10%	Yes	Yes	7	150 (7 b)
Emmerich	Ghana 2	S1 Euroimmun	S1	IgG	No<10%	Yes	Yes	4	133 (3 b)
Emmerich	Ghana 2	Nmod Euroimmun	N	IgG	No<10%	Yes	Yes	34	133 (21 b)
Emmerich	Ghana 2	N EDI	N	IgG	No<10%	Yes	Yes	39	133 (15 b)
Emmerich	Ghana 2	N Mikrogen	N	IgG	No<10%	Yes	Yes	22	133 (10 b)
Emmerich	Nigeria	S1 Euroimmun	S1	IgG	No<10%	Yes	Yes	14	150 (7 b)
Emmerich	Nigeria	Nmod Euroimmun	N	IgG	No<10%	Yes	Yes	42	150 (18 b)
Emmerich	Nigeria	N EDI	N	IgG	No<10%	Yes	Yes	91	150 (19 b)
Emmerich	Nigeria	N Mikrogen	N	IgG	No<10%	Yes	Yes	26	150 (6 b)
Yadouleton	Benin	S1 (Euroimmun)	S1	IgG	No<10%	Yes	No	8	60 (1b)
Yadouleton	Benin	S1 IgA (Euroimmun)	S1	IgA	No<10%	Yes	No	7	60
Yadouleton	Benin	S1 (InBios)	S1	IgG	No<10%	Yes	No	1	60
Yadouleton	Benin	N (Euroimmun)	N	IgG	No<10%	Yes	No	8	60 (1b)
Nzoghe	Gabon	N all subclasses	N	All Ig	No<10%	Yes	Yes	32	135
Woodford	Mali	S	S	IgG	No<10%	Yes	Yes	21	312
Woodford	Mali	N	N	IgG	No<10%	Yes	Yes	116	233
Woodford	Mali	RBD	RBD	IgG	No<10%	Yes	Yes	73	312

Baker	Uganda	Spike RBD IgM	RBD	IgM	No<10%	Yes	No	31	1077
Baker	Uganda	Spike RBD IgG	RBD	IgG	No<10%	Yes	No	7	1077
Souris	DR Congo 1+2	S1	S1	IgG	No<10%	Yes	Yes	110	574
Souris	DR Congo 1+2	S2	S2	IgG	No<10%	Yes	Yes	45	574
Souris	DR Congo 1+2	S1-RBD	RBD	IgG	No<10%	Yes	Yes	33	574
Souris	DR Congo 1+2	S1-NTD	NTD	IgG	No<10%	Yes	Yes	32	574
Souris	DR Congo 1+2	N	N	IgG	No<10%	Yes	Yes	42	574
Souris	Cameroon	S1	S1	IgG	Yes>10%	Yes	Yes	124	383
Souris	Cameroon	S2	S2	IgG	Yes>10%	Yes	Yes	69	383
Souris	Cameroon	S1-RBD	RBD	IgG	Yes>10%	Yes	Yes	85	383
Souris	Cameroon	S1-NTD	NTD	IgG	Yes>10%	Yes	Yes	23	383
Souris	Cameroon	N	N	IgG	Yes>10%	Yes	Yes	22	383
Souris	R Congo	S1	S1	IgG	No<10%	Yes	Yes	64	384
Souris	R Congo	S2	S2	IgG	No<10%	Yes	Yes	31	384
Souris	R Congo	S1-RBD	RBD	IgG	No<10%	Yes	Yes	28	384
Souris	R Congo	S1-NTD	NTD	IgG	No<10%	Yes	Yes	19	384
Souris	R Congo	N	N	IgG	No<10%	Yes	Yes	29	384
ge	Nigeria	S1 Abbott	S1	IgG	Yes>10%	Yes	Yes	0	100
ge	Nigeria	N Eurommun	N	IgG	Yes>10%	Yes	Yes	3	100
ge	Nigeria	S Eurommun	S	IgG	Yes>10%	Yes	Yes	0	100
ge	Nigeria	N or S2 Mologic	N+S2	IgG	Yes>10%	Yes	Yes	16	100
Traore	Mali	S	S	IgG	No<10%	Yes	Yes	62	283
Traore	Mali	RBD	RBD	IgG	No<10%	Yes	Yes	19	283
Traore	Mali	RBM	RBM	IgG	No<10%	Yes	Yes	25	283
ngoba	R Congo	Virotech	N	IgG	No<10%	Yes	Yes	3	82
Diagne	Senegal	N or S2	N+S2	IgG	No<10%	Yes	Yes	88	272
Diagne	Senegal	N	N	IgG	No<10%	Yes	Yes	32	152
Yansouni	Senegal	N (Abbott Architect)	N	IgG	No<10%	Yes	Yes	8	90
Yansouni	Senegal	N IgM (Standard Q-SD)	N	IgM	No<10%	Yes	Yes	9	100
Yansouni	Senegal	N IgG (Standard Q-SD)	N	IgG	No<10%	Yes	Yes	1	100
riemenam	Nigeria	Tetracore RBD	RBD	IgG	Yes>10%	Yes	Yes	2	99
riemenam	Nigeria	Tetracore N	N	IgG	Yes>10%	Yes	Yes	8	99
riemenam	Nigeria	Tetracore RBD-N	RBD+N	IgG	Yes>10%	Yes	Yes	1	99
riemenam	Nigeria	SARS2MBA S	S	IgG	Yes>10%	Yes	Yes	1	98
riemenam	Nigeria	SARS2MBA RBD541	RBD	IgG	Yes>10%	Yes	Yes	3	98

riemenam	Nigeria	SARS2MBA RBD591	RBD	IgG	Yes>10%	Yes	Yes	3	98
riemenam	Nigeria	SARS2MBA N	N	IgG	Yes>10%	Yes	Yes	14	98
riemenam	Nigeria	xMAP N	N	IgG	Yes>10%	Yes	Yes	7	100
riemenam	Nigeria	xMAP RBD	RBD	IgG	Yes>10%	Yes	Yes	2	100
riemenam	Nigeria	xMAP S1	S1	IgG	Yes>10%	Yes	Yes	0	100
riemenam	Nigeria	RightSign S RBD	S	IgG/IgM	Yes>10%	Yes	Yes	0	100
riemenam	Nigeria	Tetracore RBD	RBD	IgG	Yes>10%	Yes	Yes	11	200
riemenam	Nigeria	Tetracore N	N	IgG	Yes>10%	Yes	Yes	44	200
riemenam	Nigeria	Tetracore RBD-N	RBD+N	IgG	Yes>10%	Yes	Yes	12	200
riemenam	Nigeria	SARS2MBA S	S	IgG	Yes>10%	Yes	Yes	1	198
riemenam	Nigeria	SARS2MBA RBD541	RBD	IgG	Yes>10%	Yes	Yes	11	198
riemenam	Nigeria	SARS2MBA RBD591	RBD	IgG	Yes>10%	Yes	Yes	8	198
riemenam	Nigeria	SARS2MBA N	N	IgG	Yes>10%	Yes	Yes	8	198
riemenam	Nigeria	xMAP N	N	IgG	Yes>10%	Yes	Yes	30	200
riemenam	Nigeria	xMAP RBD	RBD	IgG	Yes>10%	Yes	Yes	8	200
riemenam	Nigeria	xMAP S1	S1	IgG	Yes>10%	Yes	Yes	0	200
riemenam	Nigeria	RightSign S	S	IgG/IgM	Yes>10%	Yes	Yes	0	200
teinhardt	Nigeria	N (Euroimmun)	N	IgG	Yes>10%	Yes	Yes	38	213 (7b)
teinhardt	Nigeria	N (Abbott)	N	IgG	Yes>10%	Yes	Yes	13	212
elanew	Ethiopia	RBD	RBD	IgG	No<10%	No	Yes	30	365
ebrecherkos	Ethiopia	LFIA-Canea, (N and S)	N+S	IgM	No<10%	No	Yes	0	50
ebrecherkos	Ethiopia	LFIA-Canea, (N and S)	N+S	IgG	No<10%	No	Yes	0	50
ebrecherkos	Ethiopia	LFIA-Canea, (N and S)	N+S	IgG/IgM	No<10%	No	Yes	0	50
ebrecherkos	Ethiopia	LFIA Cellex (N and S)	N+S	IgM	No<10%	No	Yes	0	50
ebrecherkos	Ethiopia	LFIA Cellex (N and S)	N+S	IgG	No<10%	No	Yes	0	50
ebrecherkos	Ethiopia	LFIA Cellex (N and S) (N and S)	N+S	IgG/IgM	No<10%	No	Yes	0	50
ebrecherkos	Ethiopia	LFIA-VivaCheck (N and S)	N+S	IgM	No<10%	No	Yes	0	50
ebrecherkos	Ethiopia	LFIA-VivaCheck (N and S)	N+S	IgG	No<10%	No	Yes	0	50

Gebrecherkos	Ethiopia	LFIA-VivaCheck (N and S)	N+S	IgG/IgM	No<10%	No	Yes	0	50
Gebrecherkos	Ethiopia	LFIA-Innovita (N and S)	N+S	IgM	No<10%	No	Yes	2	50
Gebrecherkos	Ethiopia	LFIA-Innovita (N and S)	N+S	IgG	No<10%	No	Yes	0	50
Gebrecherkos	Ethiopia	LFIA-Innovita (N and S)	N+S	IgG/IgM	No<10%	No	Yes	2	50
Gebrecherkos	Ethiopia	ECLIA Roche (N)	N	All Ig	No<10%	No	Yes	0	50
Mboumba Bouassa	Central Africa Republic	BIOSYNEX IgG	RBD	IgG	Yes>10%	Yes	No	0	100
Mboumba Bouassa	Central Africa Republic	BIOSYNEX IgM	RBD	IgM	Yes>10%	Yes	No	3	100
Mboumba Bouassa	Central Africa Republic	SIENNA IgG	RBD	IgG	Yes>10%	Yes	No	0	100
Mboumba Bouassa	Central Africa Republic	SIENNA IgM	RBD	IgM	Yes>10%	Yes	No	8	100
Mboumba Bouassa	Central Africa Republic	NG-test IgG	Unknown	IgG	Yes>10%	Yes	No	1	95
Mboumba Bouassa	Central Africa Republic	NG-test IgM	Unknown	IgM	Yes>10%	Yes	No	9	95
Vanroye	Diverse countries	Toda IgG/IgM (N)	N	IgG/IgM	Unknown	Yes	No	6	195
Vanroye	Diverse countries	Cellex IgG/IgM (N+S)	N+S	IgG/IgM	Unknown	Yes	No	7	195
Vanroye	Diverse countries	Mutli-G IgG/IgM (N+RBD+S)	N+RBD+S	IgG/IgM	Unknown	Yes	No	13	195
Vanroye	Diverse countries	Sure Screen IgG/IgM (N+RBD)	N+RBD	IgG/IgM	Unknown	Yes	No	14	195
Vanroye	Diverse countries	Strong Strep IgG/IgM (N+S)	N+S	IgG/IgM	Unknown	Yes	No	17	195
Vanroye	Diverse countries	QuickZen IgG/IgM (RBD)	RBD	IgG/IgM	Unknown	Yes	No	24	195
Vanroye	Diverse countries	Biohit IgG/IgM (N)	N	IgG/IgM	Unknown	Yes	No	31	195
Vanroye	Diverse countries	Singuway IgG/IgM (N+RBD)	N+RBD	IgG/IgM	Unknown	Yes	No	41	195
Vanroye	Diverse countries	Panbio IgG/IgM (N)	N	IgG/IgM	Unknown	Yes	No	44	195
Vanroye	Diverse countries	Dynamiker IgG/IgM (N+S)	N+S	IgG/IgM	Unknown	Yes	No	57	195
Vanroye	Diverse countries	Healgen IgG/IgM (S)	S	IgG/IgM	Unknown	Yes	No	96	195
Vanroye	Diverse countries	Wanti (ND) (S)	S	Unclear	Unknown	Yes	No	78	195
Vanroye	Diverse countries	Boson IgG/IgM (N)	N	IgG/IgM	Unknown	Yes	No	100	195
Lapidus	Cameroon	S1	S1	IgG	No<10%	Yes	Yes	4	19
Lapidus	Cameroon	S1	S1	IgM	No<10%	Yes	Yes	2	19

Lapidus	Senegal1	S1	S1	IgG	No<10%	Yes	Yes	53	120
Lapidus	Senegal1	S1	S1	IgM	No<10%	Yes	Yes	40	120
Lapidus	Senegal2	S1	S1	IgG	No<10%	Yes	Yes	45	67
Lapidus	Senegal2	S1	S1	IgM	No<10%	Yes	Yes	56	67
Lapidus	BurkinaFasso1	S1	S1	IgG	No<10%	Yes	Yes	21	88
Lapidus	BurkinaFasso1	S1	S1	IgM	No<10%	Yes	Yes	10	88
Lapidus	BurkinaFasso2	S1	S1	IgG	No<10%	Yes	Yes	10	25
Lapidus	BurkinaFasso2	S1	S1	IgM	No<10%	Yes	Yes	12	25
Lapidus	Ghana	S1	S1	IgG	No<10%	Yes	Yes	37	45
Lapidus	Ghana	S1	S1	IgM	No<10%	Yes	Yes	21	45
Gdoura	Tunisia	Vidas S1 RBD	RBD	IgM	No<10%	No	No	7	119
Gdoura	Tunisia	Vidas S1 RBD	RBD	IgG	No<10%	No	No	0	119
Gdoura	Tunisia	Mindray S+N	S+N	IgM	No<10%	No	No	3	119
Gdoura	Tunisia	Mindray S+N	S+N	IgG	No<10%	No	No	5	119
Gdoura	Tunisia	Cobas N	N	All Ig	No<10%	No	No	0	119
Gdoura	Tunisia	Access S1 RBD	RBD	IgG	No<10%	No	No	0	119
Naidoo	South Africa	Elecsys N	N	All Ig	Yes>10%	No	No	1	316
Naidoo	South Africa	Elecsyn S	S	All Ig	Yes>10%	No	No	0	194
Li	Nigeria	S2	S2	IgG	Yes>10%	Yes	Yes	9	361
Li	Uganda	S2	S2	IgG	Yes>10%	Yes	No	49	399
Li	Tanzania	S2	S2	IgG	Yes>10%	No	Yes	13	234
Li	Kenya	S2	S2	IgG	Yes>10%	No	Yes	46	653

Supplementary Table 3. Data on paired IgM and IgG measurements on the same samples with the same assay

AUTHOR	COUNTRY	IgM only	IgG only	Both	None
Baker	Uganda	31	5	2	1039
Gebrecherkos	Ethiopia 1	0	0	0	50
Gebrecherkos	Ethiopia 2	0	0	0	50
Gebrecherkos	Ethiopia 3	0	0	0	50
Gebrecherkos	Ethiopia 4	2	0	0	48
Mboumpa Bouassa	Central Afr Rep 1	3	0	0	97
Mboumpa Bouassa	Central Afr Rep 2	8	0	0	92
Lapidus	Cameroon	0	2	2	15
Lapidus	Senegal 1	7	20	33	60
Lapidus	Senegal 2	17	6	39	5
Lapidus	Burkina Faso 1	3	14	7	64
Lapidus	Burkina Faso 2	5	3	7	10
Lapidus	Ghana	3	19	18	5
Gdoura	Tunisia (Vidas)	7	0	0	112
Gdoura	Tunisia (Mindray)	2	4	1	112

Supplementary Table 4. Data on *Plasmodium* parasitemia (Par) and anti-SARS-CoV-2 antibodies (Ab)

AUTHOR	Ab+Par+	Ab-Par+	Ab+/Par-	Ab-Par-
Emmerich 1	9	46	5	90
Emmerich 2	6	49	6	89
Emmerich 3	12	43	12	83
Emmerich 4	1	54	6	89

Supplementary Table 5. Data on HIV status and anti-SARS-CoV-2 antibodies (Ab)

AUTHOR	Ab+HIV+	Ab-HIV+	Ab+HIV-	Ab-HIV-
Tso Tanzania	0	7	18	80
Tso Zambia	5	38	8	48
Baker Uganda	17	442	21	597

Supplementary references – Excluded studies [with reason for exclusion]

1. Lutalo T, Nalumansi A, Olara D, Kayiwa J, Ogwang B, Odwilo E, Watera C, Balinandi S, Kiconco J, Nakaseegu J, Serwanga J, Kikaire B, Ssemwanga D, Abiko B, Nsereko C, Cotten M, Buule J, Lutwama J, Downing R, Kaleebu P. Evaluation of the performance of 25 SARS-CoV-2 serological rapid diagnostic tests using a reference panel of plasma specimens at the Uganda Virus Research Institute. Int J Infect Dis. 2021 Nov;112:281-287. [Excluded pre-pandemic samples positive by other assays]
2. Matefo L, Cloete VV, Armand BP, Dominique G, Samantha P, John F, Craig T, Daniel W, Theresa L, Sunetra G, Maréza B, Danelle VJ, Jane BF. Validation of laboratory developed serology assays for detection of IgG antibody to severe acute respiratory syndrome coronavirus 2 in the South African population. J Virol Methods. 2022 Sep;307:114571. [Calibration]
3. Nyagwange J, Kutima B, Mwai K, Karanja HK, Gitonga JN, Mugo D, Uyoga S, Tuju J, Ochola-Oyier LI, Ndungu F, Bejon P, Agweyu A, Adetifa IMO, Scott JAG, Warimwe GM. Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations. J Clin Virol. 2022 Jan;146:105061. [Assays previously developed with calibration on African samples]
4. Wiens KE, Mawien PN, Rumunu J, et al. Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 2020(1). Emerg Infect Dis 2021; 27(6): 1598-606. [Calibration]
5. Sisay A, Tesfaye A, Desale A, Ataro I, Woldesenbet Z, Nigusse B, Tayachew A, Kebede A, Desta AF. Diagnostic Performance of SARS-CoV-2 IgM/IgG Rapid Test Kits for the

Detection of the Novel Coronavirus in Ethiopia. J Multidiscip Healthc. 2021 Jan 27;14:171-180. [No pre-pandemic samples]

6. Stoddard CI, Sung K, Ojee E, Adhiambo J, Begnel ER, Slyker J, Gantt S, Matsen FA 4th, Kinuthia J, Wamalwa D, Overbaugh J, Lehman DA. Distinct Antibody Responses to Endemic Coronaviruses Pre- and Post-SARS-CoV-2 Infection in Kenyan Infants and Mothers. Viruses. 2022 Jul 12;14(7):1517. [Pre-pandemic samples cannot be separated]
7. Péré H, Mboumba Bouassa RS, Tonen-Wolyec S, Podglajen I, Veyer D, Bélec L. Analytical performances of five SARS-CoV-2 whole-blood finger-stick IgG-IgM combined antibody rapid tests. J Virol Methods. 2021 Apr;290:114067. [No African samples]
8. Tazi S, Kabbaj H, Zirar J, Zouaki A, El Amin G, El Himeur O, Seffar M. Comparative Performance Evaluation of FilmArray BioFire RP2.1 and MAScIR 2.0 Assays for SARS-CoV-2 Detection. Adv Virol. 2022 Jun 1;2022:4510900. [No pre-pandemic samples, nucleic acid assays evaluated]
9. Arinola OG, Edem VF, Rahamon SK, Yaqub SA, Fashina AO, Alonge TO. Sars-Cov-2 Infection Screening Using Two Serological Testing Methods. Niger J Physiol Sci. 2020 Dec 31;35(2):117-121. [No pre-pandemic samples]
10. Gededzha MP, Mampeule N, Jugwanth S, Zwane N, David A, Burgers WA, Blackburn JM, Grove JS, George JA, Sanne I, Scott L, Stevens W, Mayne ES. Performance of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies in South Africa. PLoS One. 2021 Jun 23;16(6):e0252317. [Pre-pandemic samples cannot be separated]

11. Hussein NA, Ali EAA, El-Hakim AE, Tabll AA, El-Shershaby A, Salamony A, Shaheen MNF, Ali I, Elshall M, Shahein YE. Assessment of specific human antibodies against SARS-CoV-2 receptor binding domain by rapid in-house ELISA. Hum Antibodies. 2022;30(2):105-115. [No pre-pandemic samples]
12. Deschermeier C, Ehmen C, von Possel R, Murawski C, Rushton B, Amuasi J, Sarpong N, Maiga-Ascofaré O, Rakotozandrindrainy R, Asogun D, Ighodalo Y, Oestereich L, Duraffour S, Pahlmann M, Emmerich P. Fcγ-Receptor-Based Enzyme-Linked Immunosorbent Assays for Sensitive, Specific, and Persistent Detection of Anti-SARS-CoV-2 Nucleocapsid Protein IgG Antibodies in Human Sera. J Clin Microbiol. 2022 Jun 15;60(6):e0007522. [Calibration of new ELISAs; also includes data with commercial Euroimmun that are eligible, but are also included in Emmerich et al.]
13. Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, Aman R, Mwangangi M, Amoth P, Kasera K, Ng'ang'a W, Rombo C, Yegon C, Kithi K, Odhiambo E, Rotich T, Orgut I, Kihara S, Otiende M, Bottomley C, Mupe ZN, Kagucia EW, Gallagher KE, Etyang A, Voller S, Gitonga JN, Mugo D, Agoti CN, Otieno E, Ndwiga L, Lambe T, Wright D, Barasa E, Tsofa B, Bejon P, Ochola-Oyier LI, Agweyu A, Scott JAG, Warimwe GM. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. Science. 2021 Jan 1;371(6524):79-82. [Calibration]
14. Crowell TA, Daud II, Maswai J, Owuoth J, Sing'oei V, Imbach M, Dear N, Sawe F, Eller LA, Polyak CS, Ake JA; AFRICOS Study Group. Severe acute respiratory syndrome coronavirus-2 antibody prevalence in people with and without HIV in rural Western Kenya, January to March 2020. AIDS. 2021 Nov 15;35(14):2401-2404. [No pre-pandemic samples]

15. Meinus C, Singer R, Nandi B, Jagot O, Becker-Ziaja B, Karo B, Mvula B, Jansen A, Baumann J, Schultz A. SARS-CoV-2 prevalence and immunity: a hospital-based study from Malawi. Int J Infect Dis. 2022 Mar;116:157-165. [Calibration]
16. Bonguili NCB, Fritz M, Lenguiya LH, Mayengue PI, Koukouikila-Koussounda F, Dossou-Yovo LR, Badzi CN, Leroy EM, Niama FR. Early Circulation of SARS-CoV-2, Congo, 2020. Emerg Infect Dis. 2022 Apr;28(4):878-880. [Calibration]
17. Serwanga J, Ankunda V, Sembera J, Kato L, Oluka GK, Baine C, Odoch G, Kayiwa J, Auma BO, Jjuuko M, Nsereko C, Cotten M, Onyachi N, Muwanga M, Lutalo T, Fox J, Musenero M, Kaleebu P; COVID-19 Immunoprofiling Team. Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months. Front Immunol. 2023 Mar 16;14:1152522. [Calibration]
18. Oluka GK, Namubiru P, Kato L, Ankunda V, Gombe B, Cotten M; COVID-19 Immunoprofiling Team; Musenero M, Kaleebu P, Fox J, Serwanga J. Optimisation and Validation of a conventional ELISA and cut-offs for detecting and quantifying anti-SARS-CoV-2 Spike, RBD, and Nucleoprotein IgG, IgM, and IgA antibodies in Uganda. Front Immunol. 2023 Mar 14;14:1113194. [Calibration]
19. Benabdessalem C, Hamouda WB, Marzouki S, Faye R, Mbow AA, Diouf B, Ndiaye O, Dia N, Faye O, Sall AA, Diagne CT, Amellal H, Ezzikouri S, Mioramalala DJN, Randrianarisaona F, Trabelsi K, Boumaiza M, Hamouda SB, Ouni R, Bchiri S, Chaaban A, Gdoura M, Gorgi Y, Sfar I, Yalaoui S, Khelil JB, Hamzaoui A, Abdallah M, Cherif Y, Petres S, Mok CKP, Escriou N, Quesney S, Dellagi K, Schoenhals M, Sarih M, Vigan-Womas I, Bettaieb J, Rourou S, Barbouche MR, Ahmed MB. Development and

comparative evaluation of SARS-CoV-2 S-RBD and N based ELISA tests in various African endemic settings. Diagn Microbiol Infect Dis. 2023 Apr;105(4):115903. [Prepandemic samples cannot be separated]

20. Briggs J, Takahashi S, Nayebare P, Cuu G, Rek J, Zedi M, Kizza T, Arinaitwe E, Nankabirwa JI, Kamya M, Jagannathan P, Jacobson K, Rosenthal PJ, Dorsey G, Greenhouse B, Ssewanyana I, Rodríguez-Barraquer I. Seroprevalence of Antibodies to SARS-CoV-2 in Rural Households in Eastern Uganda, 2020-2022. JAMA Netw Open. 2023 Feb 1;6(2):e2255978. [Calibration]
21. Vigan-Womas I, Spadoni JL, Poiret T, Taïeb F, Randrianarisaona F, Faye R, Mbow AA, Gaye A, Dia N, Loucoubar C, Ny Mioramalala DJ, Ratovoson R, Randremanana RV, Sall AA, Seydi M, Noirel J, Moreau G, Simon A, Holenya P, Meyniel JP, Zagury JF, Schoenhals M. Linear epitope mapping of the humoral response against SARS-CoV-2 in two independent African cohorts. Sci Rep. 2023 Jan 16;13(1):782. [Pre-pandemic samples used as controls for peptide array analysis]
22. Nyagwange J, Kutima B, Mwai K, Karanja HK, Gitonga JN, Mugo D, Sein Y, Wright D, Omuoyo DO, Nyiro JU, Tuju J, Nokes DJ, Agweyu A, Bejon P, Ochola-Oyier LI, Scott JAG, Lambe T, Nduati E, Agoti C, Warimwe GM. Serum immunoglobulin G and mucosal immunoglobulin A antibodies from prepandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro. Int J Infect Dis. 2023 Feb;127:11-16. [Assay previously calibrated in African samples]
23. Gdoura M, Ghaloum FB, Hamida MB, Chamsa W, Triki H, Bahloul C. Development of an in-house quantitative ELISA for the evaluation of different Covid-19 vaccines in

humans. Sci Rep. 2022 Jul 4;12(1):11298. doi: 10.1038/s41598-022-15378-1. [all relevant data already included in another article].

24. Iriemenam NC, Ige FA, Greby SM, et al. Validation of xMAP SARS-CoV-2 Multi-Antigen IgG assay in Nigeria. PLoS One. 2022 Apr 1;17(4):e0266184. [relevant data on 200/213 patients included in another article].